Related Experiment Video

Updated: Apr 5, 2026

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks
10:28

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

Published on: June 26, 2020

10.4K

Durability of Response in Children Treated With Pegylated Interferon alfa [corrected] 2a ± Ribavirin for Chronic

Kathleen B Schwarz1, Jean P Molleston, Maureen M Jonas

  • 1*Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD†Department of Pediatrics, Indiana University School of Medicine, Indianapolis‡Department of Medicine, Boston Children's Hospital, Boston, MA§Department of Pediatrics, University of Pennsylvania School of Medicine, Philadelphia||Department of Pediatrics, Seattle Children's Hospital, Seattle, WA¶Department of Pediatrics, University of California, San Francisco, San Francisco#Department of Pediatrics, University of Florida College of Medicine, Gainesville**Department of Pediatrics, Columbia University Medical Center, New York, NY††Roche Products Limited, Welwyn Garden City, UK‡‡Clinical Trials and Surveys Corporation, Owings Mills, MD.

Journal of Pediatric Gastroenterology and Nutrition
|August 19, 2015
PubMed

Insights

Long-term follow-up confirms excellent durability of sustained virological response (SVR) after pegylated interferon treatment in children with chronic hepatitis C. Higher SVR rates were observed in patients with the IL28B CC genotype.

Area of Science:

  • Hepatology
  • Virology
  • Pediatric Gastroenterology

Background:

  • Limited long-term data exist on sustained virological response (SVR) durability after pegylated interferon (PegIFN) treatment in pediatric chronic hepatitis C.
  • PegIFN alfa-2a ± ribavirin (RBV) was used in the PEDS-C trial for treatment.

Purpose of the Study:

  • To assess the long-term durability of SVR following PegIFN treatment in children.
  • To evaluate the long-term safety and tolerability of the treatment.
  • To investigate the association between IL28B genotype and treatment response.

Main Methods:

  • Prospective, multicenter, long-term follow-up (LTFU) study.
  • 38 children previously treated in the PEDS-C trial were enrolled.
  • Patients attended follow-up visits 5 and 6 years after treatment cessation, with medical history, physical exams, and lab tests.

Main Results:

  • The LTFU cohort (38 patients) was representative of the original PEDS-C cohort.
  • All 21 responders maintained undetectable hepatitis C virus RNA during LTFU (4.4-7.0 years post-SVR).
  • The IL28B CC genotype was significantly associated with achieving SVR (67% vs 30% in non-CC, P=0.028).

Conclusions:

  • Sustained virological response (SVR) after PegIFN alfa-2a treatment in children with chronic hepatitis C demonstrates excellent long-term durability.
  • SVR rates are higher in children with the IL28B CC genotype compared to non-CC genotypes.
Abstract

More Related Videos

Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix10:37

Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix

Published on: October 20, 2021

3.5K
A Protocol for Analyzing Hepatitis C Virus Replication13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

24.8K

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver.
42
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
32
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
378
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
257
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
347
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
337